111 related articles for article (PubMed ID: 1518268)
1. Cell-kinetics and biochemical pharmacology of methotrexate and 6-mercaptopurine in human malignant T-lymphoblasts.
Bökkerink JP; De Abreu RA; Stet EH; Damen FJ
Klin Padiatr; 1992; 204(4):293-8. PubMed ID: 1518268
[TBL] [Abstract][Full Text] [Related]
2. [Biochemical and clinico-pharmacological aspects of antimetabolites in the treatment of leukemia].
Bökkerink JP; de Abreu RA; Lippens RJ; Schouten TJ; de Vaan GA
Tijdschr Kindergeneeskd; 1988 Apr; 56(2):55-60. PubMed ID: 3287684
[TBL] [Abstract][Full Text] [Related]
3. Dose-related effects of methotrexate on purine and pyrimidine nucleotides and on cell-kinetic parameters in MOLT-4 malignant human T-lymphoblasts.
Bökkerink JP; De Abreu RA; Bakker MA; Hulscher TW; Van Baal JM; De Vaan GA
Biochem Pharmacol; 1986 Oct; 35(20):3557-64. PubMed ID: 2429668
[TBL] [Abstract][Full Text] [Related]
4. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RA; Schretlen ED
Biochem Pharmacol; 1988 Jun; 37(12):2321-7. PubMed ID: 2455519
[TBL] [Abstract][Full Text] [Related]
5. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.
Bökkerink JP; Stet EH; De Abreu RA; Damen FJ; Hulscher TW; Bakker MA; van Baal JA
Biochem Pharmacol; 1993 Apr; 45(7):1455-63. PubMed ID: 7682415
[TBL] [Abstract][Full Text] [Related]
6. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
7. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Takemura Y; Ohnuma T
Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
[TBL] [Abstract][Full Text] [Related]
8. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Fairbanks LD; Rückemann K; Qiu Y; Hawrylowicz CM; Richards DF; Swaminathan R; Kirschbaum B; Simmonds HA
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):143-52. PubMed ID: 10432311
[TBL] [Abstract][Full Text] [Related]
10. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RR; Schretlen ED; van Laarhoven JP; De Bruyn CH
Biochem Pharmacol; 1986 Oct; 35(20):3549-55. PubMed ID: 2429667
[TBL] [Abstract][Full Text] [Related]
11. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
[TBL] [Abstract][Full Text] [Related]
12. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy in childhood leukaemia: in vitro studies of thiopurines and inhibitors of purine metabolism on apoptosis.
De Abreu RA; Trueworthy RC; van Kuilenburg AB; Vogels-Mentink TM; Lambooy LH; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):70-4. PubMed ID: 12542913
[TBL] [Abstract][Full Text] [Related]
14. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
15. [6-Mercaptopurine and methotrexate, rational use in sight after 35 years?].
Bökkerink JP; Schouten TJ; De Abreu RA; Lippens RJ; De Vaan GA; De Bruyn CH; Van Laarhoven JP
Tijdschr Kindergeneeskd; 1984 Aug; 52(4):118-23. PubMed ID: 6593896
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group.
McGuire JJ; Russell CA; Bolanowska WE; Freitag CM; Jones CS; Kalman TI
Cancer Res; 1990 Mar; 50(6):1726-31. PubMed ID: 2306727
[TBL] [Abstract][Full Text] [Related]
17. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
[TBL] [Abstract][Full Text] [Related]
18. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
[TBL] [Abstract][Full Text] [Related]
19. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
Nakamura T; Ueda T; Uchida M
Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
[TBL] [Abstract][Full Text] [Related]
20. Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia.
Nygaard U; Schmiegelow K
Leukemia; 2003 Jul; 17(7):1344-8. PubMed ID: 12835723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
